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220 TUMORS OF THE LIVER 
SPONTANEOUS BACTERIAL PERITONITIS 
Spontaneous bacterial peritonitis ~ay occur in patient,s in 
whom cirrhosis is complicated by ascites. Symptoms and signs 
- include fever, lethargy, poor feeding, vomiting, diar~hIeaI 
diffuse abdominal pain. abdominal distention and rigIdity, 
and diffuse rebound tenderness. In up to 15 per cent of 
patients, however, the con~ition ~ay be asymptomatic. Diag-
nostic paracenthesls IS mdlcated m all suspected ~asesK The 
ascitic fluid should be assessed for cell count and differential, 
total protein, lactate, pH (with concomitant capillary or ~rterial 
pH), and microbiologic ~tudiesI includi~~ a Gram stam and 
both aerobic and anaerobiC cultures. Antibiotic therapy should 
be initiated in all patients with an ascitic fluid polymorpho-
nuclear leukocyte count of more than 500 cells/mm3 or in any 
patient with signs of peritonitis and polymorphonuc~eKa~ le~­
kocytes of more than 250 cells/mm3 • Bef~r~ senslUvlty IS 
known, ampicillin (200 mg/kg/day), gentamlCm (7.5 mg/kg/ 
day), and clindamycin (30 m~/kg/dayF should be starte~iK 
Decreased ascitic fluid pH and mcreased lactate may help f~ 
establishing the diagnosis; however, awareness of the condi-
tion remains the kev to diagnosis. 
LIVER TRANSPLANTATION 
Unfortunatelv. in manv patients with chronic liver disease 
and in hepatic failure, orthotopic liver transplantationmav be 
the onlv remaining consideration. Poor prognostIc signs in-
dicative of the need for liver transplantation include ( 1) serum 
bilirubin greater than 10 to 15 mg/dl, (2) serum albumin less 
than 2.5 g/dl, (3) presence of hepatic encephalopathy, (4) 
prothrombin time greater than 5 seconds above contr?l, (5) 
presence of the hepatorenal syndrome: (6) re~urr~~t eplsod~s 
of cholangitis, (7) spontaneous bactenal pentonItis or septi-
cemia, (8) intractable ascites, and (9) the development of focal 
hepatocellular carcin<;>ma. In the past, the require~ent for, a 
size-matched donor hver had contnbuted to the difficulty III 
obtaining organs for pediatric recipients. Currently, t~e use 
of segmental transplantation has increased the proportl,on of 
candidates transplanted and reduced the overall mortahty. 
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Increasing numbers of hepatic mass lesions are found 
incidentally by advanced imaging technology. Although most 
of these "incidental" tumors are histologically benign and do 
not require any therapy, they ~ust b~ thorou,ghly ~nvestigat~dK 
Modern imaging technology IS qUite effiCient m detectlll:g 
small lesions but is not effective in producing pathognomOnIc 
findings of many hepatic lesions other than hemangiomas and 
cysts. Percutaneous needle biI?ps~ ~ften fails .to establ,ish a 
definitive diagnosis because of Its hml~ed samplmg, and It can 
cause serious hemorrhage when unWisely performed for vas-
cular lesions. 
Major hepatic resections can now be performed with mini-
mum operative risk (less than 5 per cent), but no surgeon 
should explore a hepatic mass with?ut h~ving ~he competence 
to perform all of the major reseCtions, mcludmg a nght and 
left trisegmentectomy, 
BENIGN TUMORS 
Most of the benign tumors of the l~ver are asym~tomatic 
and are found incidentally during studies for other disorders 
or during abdominal operations. The general approach to a 
small incidental tumor (less than 3 cm in diameter) that is 
considered benign is close observation after "thorough" in-
vestigation. When the tumor changes its imaging characteris-
tics or increases in size during close observation, it must be 
immediately excised. Larger incidental tumors, other than 
asymptomatic cavernous hemangiomas, deserve excisional 
therapy unless unequivocal benignity is confirmed. 
Hemangiomas are the most common benign tumors of the 
liver. Giant cavernous hemangiomas should be treated by 
surgical excision, particularly when they are symptomatic EeK~KI 
pain, mass-related complaints) or are found to have a necrotic 
center inside. The majority of giant cavernous hemangiomas 
require lobectomies or trisegmentectomies of the liver, but 
some located on the surface of the liver or pedunculated can 
be enucleated along pseudocapsular margins without signifi-
cant loss of normal liver tissue. Ligation or embolization of 
the feeding hepatic artery and radiation therapy may be 
hazardous and do not have long-standing effects on the course 
of giant cavernous hemangiomas. 
Infantile hemangioendotheliomas are most often seen in 
infants during the first 6 months of life and are distinct from 
cavernous hemangiomas. The lesions should be excised by 
anatomic hepatic resection whenever possible. Treatment with 
prednisone, diuretics, and digoxin can be used initially when 
the patient'S condition prohibits surgery or the lesion is too 
extensive for resection. Response to prednisone may allow 
surgery to be performed safely in a few weeks. In extensive 
lesions, radiation to the liver may be used after pathologic 
diagnosis is confirmed. Favorable responses to steroids, radia-
tion, and hepatic artery ligation or embolization have been 
reported. The treatment should be vigorous, because com-
plete regression and cure are possible. 
Other benign tumors include liver cell adenoma, focal 
nodular hyperplasia, hematoma, mesenchymoma, teratoma, 
and fibroma. Radiologic differentiation of these benign tu-
mors from malignant tumors is unreliable. Pathologic confir-
mation of benign tumors is mandatory for each lesion. Large 
benign tumors should be treated by surgical excision, partic-
ularly when they are symptomatic. Adenoma has a tendency 
to rupture and cause life-threatening hemorrhage. Some 
adenomas cannot be easilv differentiated from low-grade 
hepatocellular carcinoma by needle biopsies. If the diagnosis 
is uncertain, the lesion should be excised with an adequate 
margin without delay. 
Congenital hepatic cysts are usually asymptomatic and do 
not require any therapy. Although aspiration, internal drain-
age, marsupialization, fenestration, and sclerotherapy have all 
been recommended for symptomatic congenital cysts, these 
approaches are no longer justifiable for the treatment of 
single or localized multiple cysts because hepatic resections 
can be performed quite safely now. 
MALIGNANT TUMORS 
The most common primary malignant tumor of the liver in 
children is hepatoblastoma. Hepatocellular carcinoma is the 
second most common and usuallv occurs in older children. 
Sarcomas of the liver, such as rhabdomyosarcoma and angio-
sarcoma, are rare. None of these has a favorable outlook, but 
fibrolamellar hepatocellular carcinoma, which is common in 
older children and young adults, has a better prognosis than 
other types of malignancy. 
The treatment for all malignant liver tumors is complete 
surgical excision by anatomic hepatic resection. Hepatic resec-
tions of more than the right or left lobe of the hver can be 
performed quite safely. For example, a large tumor occupying 
the right lobe of the liver and the medial segment of the left 
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lobe can be resected by right hepatic trisegmentectomv. leav-
ing only the left lateral segment of the left lobe (to the left of 
the falciform ligament). or a large tumor occupying the left 
lobe and the anterior segment of the right lobe can be resected 
by left hepatic trisegmentectomy. leaving on Iv the posterior 
segment of the right lobe (posterior to the right hepatic vein). 
These major hepatic resections can now be performed bv 
experienced surgeons with less than a 5 per cent operative 
mortalitv. 
We h~ve found that computed tomographv scan or mag-
netic resonance imaging is most useful in assessing the extent 
of the tumor, but findings can be misleading, particularly 
when a large tumor distorts normal anatomic boundaries. If 
the resectability is uncertain after extensive preoperative in-
vestigation. the patient should be referred to a surgeon who 
is experienced in major hepatic resection rather than undergo 
exploratory celiotomy by someone who is unprepared to 
undertake a definitive procedure. 
After curative hepatic resection. we usually recommend that 
patients receive adjuvant chemotherapy for at least I year. 
We have been using combination chemotherapy with doxo-
rubicin. dactinomycin, vincristine. and cyclophosphamide, and 
often mitomvcin or cisplatin. The value of this approach has 
not been validated in randomized trials. but the patients who 
have received adjuvant chemotherapv after curative resections 
of large tumors have seemed to have longer tumor-free 
survival. 
In general. liver transplantation (total hepatectomy and 
liver replacement) cannot offer good long-term results when 
applied to large malignant tumors that cannot be removed bv 
subtotal hepatectomy. However. liver transplantation can re-
sult in a cure (more than 5-year survival) on more than 
isolated occasions. The most favorable lesions for transplan-
tation, just as with resection. are the fibrolamellar hepatoma 
and epithelioid hemangioendothelial sarcoma. On the other 
hand, most of the patients who have received liver transplan-
tation for other end-stage liver diseases. such as tyrosinemia 
and alpha,-antitrypsin deficiency disease. and whose malig-
nant tumors were small and incidental. survived tumor-free 
for several years. 
The most common metastatic liver tumors in children are 
neuroblastoma and Wilms' tumor. Although chemotherapy 
and radiation therapy mav be helpful in treating these meta-
static tumors. the lesion should be excised whenever possible. 
particularlv if it is localized to part of the liver. Hepatic 
resections for metastatic tumors are much safer than those 
for primary malignancy. 
PORTAL HYPERTENSION 
JOHN T. BOYLE, M.D. 
Portal hypertension in childhood may be classified as intra-
hepatic or extrahepatic. Intrahepatic portal hypertension results 
from cirrhosis. which in the United States is most commonly 
caused bv biliary atresia. chronic viral or autoimmune hepa-
titis, or alpha,-antitrypsin deficiency. Extrahepatic portal hy-
pertension is most commonly caused by portal vein thrombosis 
(cavernous transformation of the portal vein) or by hepatic 
venous or inferior vena caval obstruction (Budd-Chiari syn-
drome). The etiology in individual patients is usually sug-
gested bv real-time ultrasonography and Doppler flowmetry. 
Although anatomv of the portal circulation is best defined by 
angiography. information such as site of portal vein obstruc-
tion, distribution of collaterals. and dynamics of portal flow is 
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of therapeutic importance only when shunt surgery is being 
contemplated. 
Portal hypertension results in splenomegaly and esophageal 
varices. Clinical presentations include asymptomatic spleno-
megaly (with or without laboratory evidence of thrombocvto-
penia. anemia. or neutropenia), upper gastrointestinal (GI) 
bleeding from ruptured esophageal or gastric varices, or. 
rarely. ascites or bleeding hemorrhoids. In patients who 
present for the first time with upper GI bleeding. the possi-
bility of bleeding esophageal varices is primarily suggested bv 
a past history of jaundice. hepatitis. blood transfusion. sepsis. 
shock. chronic right-sided heart failure. pulmonary hyperten-
sion. exchange transfusion. omphalitis. or umbilical vein cath-
eterization. 
Because there are few reports in the pediatric literature 
regarding the management of variceal bleeding. therapy is 
based primarily on the adult experience. It is important to 
emphasize that there is no consensus on management policy 
in pediatric patients before. during. or after variceal bleeding. 
TREATMENT 
Management of Splenomegaly in Patients with Portal Hypertension 
Everv effort should be made to ensure that a child with 
portal hvpertension leads as normal a life as possible. Normal 
school activity should be allowed with the exception of contact 
sports and physical education activities involving prolonged 
running or jumping. Oftentimes. education of school officials 
is required to explain signs and symptoms of bleeding. 
Although hypersplenism is a common complication of sple-
nomegaly in patients with portal hypertension. bleeding and 
infection related to thrombocytopenia and neutropenia are 
rare. Hypersplenism is not an indication for splenectomv in 
such patients. Nevertheless. the presence of fever in a patient 
with portal hypertension demands immediate and careful 
evaluation to identify a source of infection. It is my practice 
to recommend pneumococcal immunization to patients with 
cirrhosis and hypersplenism. 
Prophylactic Management to Prevent the First Variceal Bleed 
Patients should avoid nonsteroidal anti-inflammatory 
agents, which may cause GI inflammation or ulceration:. 
Coughing associated with upper respiratory infections should 
be treated with antitussive agents. 
The risk of first-time variceal bleeding in children with 
known portal hypertension is unknown. In adults. only 25 to 
30 per cent of patients with esophageal varices will experience 
variceal hemorrhage. Therefore. the risk-benefit ratio is 
widely believed to be against the use of repeated sclerotherapy 
and shunt surgery as prophylactic therapy prior to the first 
variceal bleed. In adults, a number of randomized. double-
blind trials have now reported a statistically significant reduc-
tion in the frequency of variceal bleeding for patients while 
on chronic beta-blocker therapy. Results have been best in 
patients with Child Class A or B (an index of liver dysfunction 
based on serum albumin. serum bilirubin, prothrombin time. 
and the presence of ascites and encephalopathy). 
The main argument for prophylactic use of beta-blockade 
therapy is that there is little to lose. In the absence of cardiac 
decompensation. heart block. and reactive airway disease. 
propranolol appears to have a wide margin of safety in 
pediatric patients. It is imperative to remember that during 
acute bleeds propranolol may mask compensatory hemody-
namic changes. a fact that must be taken into account during 
resuscitative efforts. 
Patients with documented portal hypertension should 
undergo endoscopy at least every 2 years. In patients judged 
likely to be compliant. a decision to use prophylactic propran-
